---
company: IOVANCE BIOTHERAPEUTICS, INC.
ticker: IOVA
form: 8-K
filed: 2026-05-07
accession: 0001104659-26-056782
source: https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/
---

# Iovance Biotherapeutics (IOVA) earnings release, May 7, 2026

Iovance Biotherapeutics, Inc. (IOVA) · Form 8-K, Item 2.02 · Filed 2026-05-07 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1425205/000110465926056782/)

Iovance Biotherapeutics Highlights Positive

First Quarter 2026

Results, Business Achievements and Corporate

Updates

1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year

Growth

2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M

40% Confirmed Objective Response Rate in Metastatic

Serous Endometrial Cancer

SAN CARLOS, Calif., May 7, 2026 --

Iovance Biotherapeutics, Inc.

(NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today reported first quarter 2026 financial results, business achievements, and corporate updates.

Frederick Vogt, Ph.D., J.D., Interim President and Chief Executive

Officer of Iovance, stated, “We are accelerating the adoption and commercial expansion for Amtagvi after record high demand. Iovance is well positioned through 2026 for long-term revenue growth, while advancing multiple ongoing and new clinical trials, including our registrational trial in advanced sarcomas now underway and encouraging initial data reported today for lifileucel in metastatic serous endometrial cancer. Internal manufacturing efficiencies, operational improvements, and cost reductions will benefit gross margin and propel future profitability, sustainable growth, and long-term value for patients and shareholders.”

First Quarter 2026 Financial

Highlights

Continued Strength in Execution and Cost Discipline

Second Quarter 2026 and Full

Year 2026 Guidance

Strong Growth in Amtagvi Forecast for 2026

Amtagvi Commercial Business

Strong U.S. Commercial Business to Deliver Strong Growth in 2026

Pipeline Updates

New Data Across Several Pipeline Programs

Anticipated Throughout 2026

Corporate Updates

Webcast and Conference Call

Management will host a conference call and live audio webcast to discuss these results and provide a corporate update today at 8:30 a.m. ET. To listen to the live or archived audio webcast, please register at https://edge.media-server.com/mmc/p/wmx3s4fc. The live and archived webcast can be accessed in the Investors section of the

Company’s website, IR.Iovance.com, for one year.

1.Hamilton, C., Cheung, M., Osann, K. et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94, 642–646

2. Surveillance, Epidemiology, and End Results Program

Cancer Stat

Facts

(accessed May 2026).

3. Zhang L, Rosenberg SA, et al, Clin Cancer Res 2015;21(10):2278–2288.

4. Cash, cash equivalents, short-term investments, and restricted cash as of March 31, 2026.

About Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient.

The

Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance’s Amtagvi® is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Amtagvi® and its accompanying design marks, Proleukin®, Iovance®, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries.

All other trademarks and registered trademarks are the property of their respective owners.

Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on www.iovance.com.

Forward-Looking Statements

Certain matters discussed in this press release are “forward-looking statements” of Iovance Biotherapeutics, Inc. (hereinafter referred to as the

“Company,” “we,” “us,” or “our”) within the meaning of the Private Securities

Litigation Reform Act of 1995 (the “PSLRA”). Without limiting the foregoing, we may, in some cases, use terms such as

“predicts,” “believes,” “potential,” “achievable,” “continue,”

“estimates,” “anticipates,” “expects,” “plans,” “intends,”

“forecast,” “guidance,” “outlook,” “may,” “can,” “could,”

“might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including... (truncated)Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products; the acceptance by the market of our products and product candidates, if approved, and their potential pricing and/or reimbursement by payors, and whether such acceptance is sufficient to support continued commercialization or development of our products or product candidates; the risk regarding our ability to manufacture our therapies at our i

CTC facility, including the risk that our ability to increase manufacturing capacity at our facility may adversely affect our commercial launch; the risk that the successful development or commercialization of our products may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain regulatory authority approval of our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with regulatory authorities may support registrational studies and subsequent approvals by regulatory authorities, including the risk that the planned registrational trial in advanced sarcomas may not support approval; preliminary and interim clinical results, which may include efficacy and safety results, from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities; the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the risk that we may not be able to recognize revenue for our products; the risk that Proleukin revenues, and other factors such as the number of

ATCs, may not serve as a leading indicator for Amtagvi revenues; the risks regarding our anticipated operating and financial performance, including our financial guidance and projections; the effects of global and domestic geopolitical factors or public health events; and other factors, including general economic conditions and regulatory developments, not within our control. Any financial guidance provided in this press release assumes the following: no material change in our ability to manufacture our products; no material change in payor coverage; no material change in revenue recognition policies; no new business development transactions not completed as of the period covered by this press release; and no material fluctuation in exchange rates.

IOVANCE BIOTHERAPEUTICS, INC.

Selected Condensed Consolidated Balance Sheets

(in thousands)

Condensed Consolidated Statements of Operations

(in thousands, except per share information)

CONTACTS

Investors

IR@iovance.com

650-260-7120 ext. 150

Media

PR@iovance.com

650-260-7120 ext. 150

## Financial statements

### Income Statement (For the Three Months Ended — (in thousands, except per share information))

| | For the Three Months Ended – March 31, – 2026 (unaudited) | For the Three Months Ended – March 31, – 2025 (unaudited) |
|---|---:|---:|
| Revenue | Product revenue, net | 71,430 | 49,324 |
| Revenue | Total revenue | 71,430 | 49,324 |
| Costs and expenses* | Cost of sales ** | 42,498 | 42,715 |
| Costs and expenses* | Research and development ** | 62,487 | 75,965 |
| Costs and expenses* | Selling, general and administrative ** | 38,949 | 43,800 |
| Costs and expenses* | Depreciation and amortization | 8,539 | 8,065 |
| Costs and expenses* | Total costs and expenses | 152,473 | 170,545 |
| Costs and expenses* | Loss from operations | -81,043 | -121,221 |
| Other income | Interest and other income, net | 1,333 | 3,220 |
| Other income | Net Loss before income taxes | -79,710 | -118,001 |
| Other income | Income tax (expense) benefit | 665 | 1,838 |
| Other income | Net Loss | -79,045 | -116,163 |
| Other income | Net Loss Per Share of Common Stock, Basic and Diluted | -0.19 | -0.36 |
| Other income | Weighted-Average Shares of Common Stock Outstanding, Basic and Diluted | 418,511 | 322,868 |
| *Non-cash stock-based compensation included in cost of sales and operating expenses: | Cost of sales | 1,019 | 2,420 |
| *Non-cash stock-based compensation included in cost of sales and operating expenses: | Research and development | 5,117 | 9,917 |
| *Non-cash stock-based compensation included in cost of sales and operating expenses: | Selling, general and administrative | 5,133 | 10,578 |
| *Non-cash stock-based compensation included in cost of sales and operating expenses: | Total stock-based compensation included in costs and expenses | 11,269 | 22,915 |

### Balance Sheet (December 31, 2025 — (in thousands))

| | March 31, 2026 (unaudited) | December 31, 2025 |
|---|---:|---:|
| Cash, cash equivalents, and investments | 313,443 | 296,980 |
| Restricted cash | 5,992 | 5,980 |
| Total assets | 925,665 | 913,170 |
| Stockholders' equity | 721,754 | 698,583 |
